

Open Peer Review on Qeios

EGFR Mutant-specific Inhibitor D-0316

National Cancer Institute

Source

National Cancer Institute. <u>EGFR Mutant-specific Inhibitor D-0316</u>. NCI Thesaurus. Code C156773.

An orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity. Upon administration, the EGFR mutant-specific inhibitor D-0316 specifically binds to and inhibits EGFR T790M, a secondarily acquired resistance mutation, which prevents EGFR-mediated signaling and leads to cell death in EGFR T790M-expressing tumor cells. Compared to some other EGFR inhibitors, D-0316 may have therapeutic benefits in tumors with T790M-mediated drug resistance. EGFR, a receptor tyrosine kinase that is mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.

Qeios ID: WLY5JT · https://doi.org/10.32388/WLY5JT